After approval in late 2024, Johnson & Johnson's Varipulse PFA system started 2025 on the wrong foot: Its early rollout had ...

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

Convergent hybrid ablation is an innovative treatment for a type of irregular heart rhythm called atrial fibrillation (AFib). The treatment is a two-stage procedure that combines the expertise of our ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond ...

Lazio have confirmed that head coach Maurizio Sarri has had a successful operation on his heart after being diagnosed with ...

Only a few months after Medtronic completed its acquisition of cardiac device maker Affera, the nearly billion-dollar buyout is already paying off. A dual-use catheter originally developed by Affera ...

Pulse Biosciences PLSE recently announced that the FDA has granted Investigational Device Exemption (“IDE”) approval to ...

Abbott scored two device approvals for its cardiac ablation catheters for treating abnormal heart rhythms—one on each side of the pond. In Europe, the company received a CE Mark for its Tactiflex ...

Thermedical®, a developer of advanced thermal-ablation technologies, today announced that the first patient has been treated ...

SRM Global Hospitals successfully treated an 80-year-old patient with irregular heart rhythm using advanced TactiFlex catheter ablation technology.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. HRS and ACC issued a scientific statement of guiding ...